ArticleStroke (Hoboken, N.J.)2024
Nerinetide Reduces Early Infarct Growth Among Stroke Patients Undergoing EVT Without Intravenous Alteplase.
Article in Stroke (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Nerinetide in Acute Ischemic Stroke Patients: A Systematic Review, Meta-Analysis and Meta Regression.Brain and behavior · 2025Pooled it
- Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE-NEXT: A Multicenter, Double-Blind, Randomized Controlled Trial.Journal of the American Heart Association · 2026Trial
- Molecular Mechanisms and Targeted Intervention Strategies of Calcium Overload in Ischemic Stroke.International journal of molecular sciences · 2026Review
- Therapeutic potential of nerinetide in acute ischemic stroke: a comprehensive systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nerinetide treatment was associated with better clinical outcomes among patients with stroke undergoing endovascular treatment who were not treated with concurrent alteplase in the randomized ESCAPE-NA1 (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke) trial. In patients receiving alteplase, no such effect was seen due to an inactivation of nerinetide by plasmin - the product of tissue plasminogen activation. We hypothesized that improved outcomes in the no-alteplase patients were associated with reduced infarct growth, a radiological correlate of improved stroke outcomes. Methods: Data are from the no-alteplase stratum of the ESCAPE-NA1 trial. Patients who underwent computer tomography perfusion (CTP) as part of routine clinical care were included. Admission CTP source data were processed using RAPID software. Infarct core at baseline was defined as areas of relative cerebral blood flow <30% on CTP. Final infarct volume was determined via manual segmentation on 24-hour CT or magnetic resonance diffusion-weighted imaging. We compared infarct growth (defined as 24-hour infarct volume minus CTP-estimated baseline infarct core) among no-alteplase patients treated with versus without nerinetide. Results: CTP maps were available in 413/1105 (37%) ESCAPE-NA1 participants. Of these, 179 (43%) were treated without alteplase, 79 (44%) received nerinetide, and 100 (56%) received placebo. Prior administration of alteplase modified the treatment effect of nerinetide on infarct growth in a multivariable model that was adjusted for age, sex, baseline infarct core volume, expanded Thrombolysis in Cerebral Infarction score, and time from baseline imaging to reperfusion ( Conclusion: Nerinetide was associated with decreased infarct growth in acute ischemic stroke patients undergoing thrombectomy without concurrent alteplase in the ESCAPE-NA1 trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.